World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
62
Citations
16608
World Ranking
3110
National Ranking
1457

Thomas R. O'Brien publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Thomas R. O'Brien sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 200 publications — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Thomas R. O'Brien D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas R. O'Brien sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 62 D-Index — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Thomas R. O'Brien is affiliated with the National Institutes of Health in the United States. Their research focuses primarily on medicine with a significant emphasis on epidemiology, hepatology, infectious diseases, oncology, and immunology. The scientific work covers both broad and specialized aspects of liver diseases, viral infections, and immune responses.

The main topics of research include:

  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Interferon and immune responses

Notable recent publications authored or co-authored by Thomas R. O'Brien include:

  • Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019, 2020, Clinical Infectious Diseases
  • COVID-19 and emerging viral infections: The case for interferon lambda, 2020, The Journal of Experimental Medicine
  • Recent Decline in Hepatocellular Carcinoma Rates in the United States, 2020, Gastroenterology
  • Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals, 2021, Alimentary Pharmacology & Therapeutics
  • Declining US Hepatocellular Carcinoma Rates, 2014-2017, 2021, Clinical Gastroenterology and Hepatology

Frequent co-authors collaborating with Thomas R. O'Brien include:

  • Ilona Argirion
  • Ruth M. Pfeiffer
  • Jill Koshiol
  • Ludmila Prokunina-Olsson
  • Meredith S. Shiels

Thomas R. O'Brien has published in multiple research venues, with a recurring presence in:

  • UNC Libraries
  • Genes and Immunity
  • Clinical Infectious Diseases
  • JAMA Oncology
  • Journal of Interferon & Cytokine Research

Best Publications

  • Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression

    Michael W. Smith;Michael Dean;Mary Carrington;Cheryl Winkler

  • A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

    Ludmila Prokunina-Olsson;Brian Muchmore;Wei Tang;Ruth M Pfeiffer

  • Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant

    Cheryl Winkler;William Modi;Michael W. Smith;George W. Nelson

  • New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention Purposes

    Robert S. Janssen;Glen A. Satten;Susan L. Stramer;Bhupat D. Rawal

  • Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.

    William A. Paxton;Scott R. Martin;Doris Tse;Thomas R. O'Brien

  • GENETIC ACCELERATION OF AIDS PROGRESSION BY A PROMOTER VARIANT OF CCR5

    Maureen P. Martin;Michael Dean;Michael W. Smith;Cheryl Winkler

  • Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study

    Thomas R. O'Brien;William A. Blattner;David Waters;M. Elaine Eyster

  • Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on the Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States

    Tania M. Welzel;Katherine A. McGlynn;Ann W. Hsing;Thomas R. O'Brien

  • Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data

    J. P.A. Ioannidis;P. S. Rosenberg;J. J. Goedert;L. J. Ashton

  • Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10.

    Hyoung Doo Shin;Cheryl Winkler;J. Claiborne Stephens;Jay Bream

  • HIV-1 infection in a man homozygous for CCR5▵32

    Thomas R O'Brien;Cheryl Winkler;Michael Dean;Julie Ae Nelson

  • Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32

    Nelson L. Michael;Julie A. E. Nelson;Vineet N. KewalRamani;George Chang

  • Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen.

    Deborah J. Anderson;Thomas R. O'Brien;Joseph A. Politch;Adriana Martinez

  • COVID-19 and emerging viral infections: The case for interferon lambda.

    Ludmila Prokunina-Olsson;Noémie Alphonse;Noémie Alphonse;Ruth E. Dickenson;Joan E. Durbin

  • IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family

    Thomas R. O'Brien;Ludmila Prokunina-Olsson;Raymond P. Donnelly

  • Prevention of heterosexual transmission of human immunodeficiency virus through couple counseling.

    N. S. Padian;T. R. O'brien;Yochi Chang;S. Glass

  • A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma

    Barham K. Abu Dayyeh;May Yang;Bryan C. Fuchs;Daniel L. Karl

  • Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates

    Kimberly Page-Shafer;Brandee L. Pappalardo;Leslie H. Tobler;Bruce H. Phelps

  • Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.

    Stephanie A. Mulherin;Stephanie A. Mulherin;Thomas R. O'Brien;John P.A. Ioannidis;John P.A. Ioannidis;James J. Goedert

  • Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.

    Thomas R. O'brien;David H. Mcdermott;John P. A. Ioannidis;Mary Carrington

  • Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.

    Thomas R. O’Brien;Ruth M. Pfeiffer

Frequent Co-Authors

James J. Goedert
James J. Goedert National Institutes of Health
Brian R. Edlin
Brian R. Edlin National Development and Research Institutes
Ruth M. Pfeiffer
Ruth M. Pfeiffer National Institutes of Health
Michael P. Busch
Michael P. Busch University of California, San Francisco
John P. A. Ioannidis
John P. A. Ioannidis Stanford University
Timothy R. Morgan
Timothy R. Morgan California State University, Long Beach
Mary Carrington
Mary Carrington Ragon Institute of MGH, MIT and Harvard
Stephen J. O'Brien
Stephen J. O'Brien Nova Southeastern University
Philip S. Rosenberg
Philip S. Rosenberg National Institutes of Health
Alex H. Kral
Alex H. Kral RTI International

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their career in health sciences related to immunology, exploring various nursing and practitioner programs can be a valuable step. Many professionals start with accredited LPN programs that offer foundational skills and are recognized nationwide. If you're exploring options that are more accessible, you might find the accredited lpn programs easy to get into a great starting point.

Moving beyond the LPN level, nurse practitioner degrees open doors to advanced clinical roles. Finding easy nurse practitioner programs to get into allows for a smoother transition while maintaining quality education standards. For those focusing on mental health, specialized Psychiatric-Mental Health Nurse Practitioner (PMHNP) programs are crucial.

When seeking the best clinical experience online, the best pmhnp programs online ensure strong clinical placement rates, which are essential for hands-on training. Additionally, affordability is a key factor for many students; hence, exploring the affordable pmhnp programs can help balance cost with quality education.

By understanding these related programs, students and professionals interested in immunology can tailor their education to suit their career goals and practical needs.

Best Scientists Citing Thomas R. O'Brien

Trending Scientists

Recently Published Articles